A man in a white coat in a pharmacy looks at a solutions bag

Phase 1: A Diverse Portfolio of Pre-Mixed CRRT Solutions

Vantive helps address the needs of patients experiencing acute kidney injury with a wide range of purposefully designed CRRT solutions.

Pre-mixed solution choices for more efficient individualized care

Vantive’s range of pre-mixed CRRT solutions enables prescription flexibility and helps streamline therapy.

Healthcare professional leans over a bassinet and has a discussion with a colleague. ThePrisMax system stands behind her.
Healthcare professional leans over a bassinet and has a discussion with a colleague. ThePrisMax system stands behind her.
Healthcare professional leans over a bassinet and has a discussion with a colleague. ThePrisMax system stands behind her.
Achieve prescribing flexibility with consistent therapy performance

With access to a comprehensive portfolio of dialysate and replacement solutions specifically designed and indicated for CRRT, clinicians can achieve prescribing flexibility for both adult and pediatric patients.1-4 

Focus on patient care with simplified therapy delivery

Our pre-mixed CRRT solutions are purposefully designed  to simplify electrolyte management for critical care patients.1-4

Maximize efficiencies with improved workflows

Our CRRT solutions are designed to reduce the potential of preparation errors associated with pharmacy-made solutions and the related liability — while improving efficiencies. Pre-mixed solutions may also help streamline processes, minimize pharmacy compounding costs, reduce the nursing burden associated with separately administering electrolytes, and help improve workflow efficiencies for the hospital.5-9

Solutions to solve specific clinical challenges

Vantive pre-mixed CRRT solutions enable clinicians to treat acid-base and electrolyte disorders and treatment-related disturbances in electrolyte homeostasis.

PrismaSate

PrismaSate Dialysate Formula is intended for treatment of acute kidney disease (renal failure) using Continuous Renal Replacement Therapies, such as continuous hemodialysis and hemodiafiltration aimed at normalizing the composition of the blood. It may also be used in case of drug poisoning with dialyzable or filterable substances.

Rx Only. For safe and proper use of the products mentioned herein, please refer to the Operator's Manual or Instructions for Use.

Learn more

PrismaSol

PrismaSol Solution provides the physician with a range of choices in response to each patient’s specific condition. Available in seven formulas varying in calcium, potassium, bicarbonate and dextrose levels.

Please see Important Risk Information and full Prescribing Information.

Learn more

Phoxillum

Phoxillum is the ONLY FDA-approved premixed CRRT replacement solution with phosphate in a 5L bag. Phoxillum renal replacement solution has been shown to reduce hypophosphatemia,10 solution preparation time,9,11 and potential for errors*12 when treating acute kidney injury (AKI) patients. 

*Due to manual compounding

Please see Important Risk Information and full Prescribing Information.

Learn more

Important Safety Information

INDICATIONS

PrismaSol and Phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT ) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

IMPORTANT RISK INFORMATION

  • Phoxillum and PrismaSol replacement solutions are contraindicated in patients with known hypersensitivities to these products. 

  • Phoxillum and PrismaSol solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. 

  • Phoxillum replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis. 

  • PrismaSol and Phoxillum replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. 

  • The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of Phoxillum or PrismaSol: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance. 

  • Please click here for full Prescribing Information.

_____

INDICATIONS AND USAGE

PrismaSate Dialysate Formula is intended for treatment of acute kidney disease (renal failure) using Continuous Renal Replacement Therapies, such as continuous hemodialysis and hemodiafiltration aimed at normalizing the composition of the blood. It may also be used in case of drug poisoning with dialyzable or filterable substances. 

 

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, Phoxillum, PrismaSate, PrismaSol and PrisMax are trademarks of Vantive Health LLC or its affiliates.

Important Safety Information

INDICATIONSPrismaSol and Phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT ) to replace plasma volu...
Full Safety Information
References

  1. Phoxillum Summary of Product Characteristics, 2018.

  2. Prismasol 2 mmol/l Potassium Summary of Product Characteristics, 2018.

  3. Prismasol 4 mmol/l Potassium Summary of Product Characteristics, 2018.

  4. Regiocit Summary of Product Characteristics, 2019.

  5. Besnard N, Serveaux M, Machado S, et al. Electrolytes-enriched hemodiafiltration solutions for continuous renal replacement therapy in acute kidney injury: a crossover study. Blood Purif. 2016;42(1):18-26.

  6. Godden J, Spexarth F, Dahlgren M. Standardization of continuous renal-replacement therapy fluids using a commercial product. Am J Health Syst Pharm. 2012;69(9):786-793.

  7. Barletta JF, Barletta GM, Brophy PD, Maxvold NJ, Hackbarth RM, Bunchman TE. Medication errors and patient complications with continuous renal replacement therapy. Pediatr Nephrol. 2006;21(6):842-845.

  8. Shaw AR, Chaijamorn W, Clark JS, Mueller BA. Preparation times and costs for various solutions used for continuous renal replacement therapy. Am J Health Syst Pharm. 2018;75(11):808-815.

  9. Jang SM, Clark JS, Mueller BA. Update on preparation of solutions for continuous renal replacement therapy. Am J Health Syst Pharm. 2018;75(13):931-932.

  10. Thompson Bastin ML, Nerusu S, Adams P, Morris P, Neyra JA. Phosphorus-containing solutions reduce incident hypophosphatemia and associate with better outcomes in critically ill patients requiring continuous renal replacement therapy. Presented at the 2019 American Thoracic Society International Conference. https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A5994

  11. Shaw AR, Chaijamorn W, Clark JS, Mueller BA. Preparation times and costs for various solutions used for continuous renal replacement therapy. Am J Health Syst Pharm. 2018;75(11):808-815.

  12. Heung M, Mueller BA. Prevention of hypophosphatemia during continuous renal replacement therapy — an overlooked problem. Semin Dial. 2018;31(3):213-218.